PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION, page-194

  1. 252 Posts.
    lightbulb Created with Sketch. 20
    hi grandslam when you say "ind approval" which end are you referring to please ie approval to commence the trial or at the outcome end when the new drug has been approved after investigation??
    2 totally different reference points of course and tanami rod has answered from approval to commence trial end I believe
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.